Williams G, Sallis J D
Calcif Tissue Int. 1982 Mar;34(2):169-77. doi: 10.1007/BF02411229.
For a compound to inhibit potently the transformation of amorphous calcium phosphate into hydroxyapatite, it is suggested that the minimum structural requirement is a phosphate group and, at some other position, either another phosphate group preferably or a carboxylic moiety. Primary amino groups abolish inhibitor potential. Inhibitor potency is modified by various secondary factors, including the number and proximity of active groups, their stereochemistry, steric factors, the lability of the molecule, and in special instances its lipophilicity. Parameters used to monitor the transformation indicate that inhibitors can be grouped into two classes, and it is suggested that this is because one class acts as a hydroxyapatite crystal growth inhibitor. The close proximity of two phosphate groups or of a phosphate and multiple carboxylic groups is proposed to determine in part whether or not a compound acts as a crystal growth inhibitor. Further, bulky side groups render a molecule inactive as a crystal growth poison, although it will still inhibit by other mechanisms.
对于一种化合物要有效抑制无定形磷酸钙向羟基磷灰石的转化,有人提出其最低结构要求是一个磷酸基团,并且在其他某个位置,最好是另一个磷酸基团或者一个羧基部分。伯氨基会消除抑制剂的潜力。抑制剂的效力会受到各种次要因素的影响,包括活性基团的数量和相邻性、它们的立体化学、空间因素、分子的稳定性,以及在特殊情况下其亲脂性。用于监测转化的参数表明抑制剂可分为两类,有人认为这是因为一类作为羟基磷灰石晶体生长抑制剂起作用。两个磷酸基团或者一个磷酸基团与多个羧基的紧密相邻被认为部分决定了一种化合物是否作为晶体生长抑制剂起作用。此外,庞大的侧基会使一个分子作为晶体生长毒物无活性,尽管它仍会通过其他机制产生抑制作用。